Standardized butanol fraction of WIN-34B suppresses cartilage destruction via inhibited production of matrix metalloproteinase and inflammatory mediator in osteoarthritis human cartilage explants culture and chondrocytes
- Jeong-Eun Huh†1Email author,
- Byung-Kwan Seo†2,
- Yong-Hyeon Baek2,
- Sanghoon Lee3,
- Jae-Dong Lee3,
- Do-Young Choi3 and
- Dong-Suk Park2
© Huh et al.; licensee BioMed Central Ltd. 2012
Received: 5 June 2012
Accepted: 12 November 2012
Published: 15 December 2012
WIN-34B is a novel Oriental medicine, which represents the n-butanol fraction prepared from dried flowers of Lonicera japonica Thunb and dried roots of Anemarrhena asphodeloides BUNGE. The component herb of WIN-34B is used for arthritis treatment in East Asian countries. The aim of this study was to determine the cartilage-protective effects and mechanisms of WIN-34B and its major phenolic compounds, chlorogenic acid and mangiferin, in osteoarthritis (OA) human cartilage explants culture and chondrocytes.
The investigation focused on whether WIN-34B and its standard compounds protected cartilage in interleukin (IL)-1β-stimulated cartilage explants culture and chondrocytes derived from OA patients. Also, the mechanisms of WIN-34B on matrix metalloproteinases (MMPs), tissue inhibitor of matrix metalloproteinases (TIMPs), inflammatory mediators, and mitogen-activated protein kinases (MAPKs) pathways were assessed.
WIN-34B was not cytotoxic to cultured cartilage explants or chondrocytes. WIN-34B dose-dependently inhibited the release of glycosaminoglycan and type II collagen, increased the mRNA expression of aggrecan and type II collagen, and recovered the intensity of proteoglycan and collagen by histological analysis in IL-1β-stimulated human cartilage explants culture. The cartilage protective effect of WIN-34B was similar to or better than that of chlorogenic acid and mangiferin. Compared to chlorogenic acid and mangiferin, WIN-34B displayed equal or greater decreases in the levels of MMP-1, MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5, and markedly up-regulated TIMP-1 and TIMP-3. WIN-34B inhibited inflammatory mediators involved in cartilage destruction, such as prostaglandin E2, nitric oxide, tumor necrosis factor-alpha, and IL-1β. The phosphorylation of extracellular signal-regulated kinase, c-Jun N-terminal kinase (JNK), and p38 was significantly reduced by WIN-34B treatment, while phosphorylation of JNK was only inhibited by chlorogenic acid or mangiferin in IL-1β-stimulated chondrocytes.
WIN-34B is potentially valuable as a treatment for OA by virtue of its suppression of MMPs, ADAMTSs, and inflammatory mediators, and it’s up-regulation of TIMP-1 and TIMP-3 involved in the MAPK pathway.
KeywordsWIN-34B Standard compounds Cartilage protection Matrix proteinases Inflammatory mediators
Osteoarthritis (OA) is a multifactorial degenerative joint disease in which the cartilaginous matrix of the articular joint is destroyed. The anabolic and catabolic imbalance in articular cartilage plays a crucial role in OA pathogenesis. As a result, enhanced degradation occurs in the macromolecular components including aggrecan and collagen . The superficial zone of OA cartilage, which is characterized by degenerative changes (fibrillations, chondrocyte clusters, and degenerative matrix changes) contains interleukin (IL)-1β, tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinases (MMPs) including MMP-1, 2, 3, 8, 9, and 13 . IL-1β and TNF-α can induce chondrocytes to produce other cytokines as well as stimulate catabolic proteinases (MMPs or aggrecanases) and proinflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2) . In this way, they can alter compensatory biosynthetic homeostasis and, in turn, break down the integrity of the extracellular matrix (ECM) [4–6].
The disease progression and structural changes show that the release of sulfated glycosaminoglycan (GAG), the degradation of type II collagen, and the over-production of cytokines are central pathophysiological events in OA. The course of the disease is related to a number of complex pathways and mechanisms, among which are the excessive production of proteolytic enzymes such as the aggrecanases and MMPs [4–6]. Aggrecan is degraded by both aggrecanases and MMPs, whereas type II collagen is degraded by MMPs . With these protease activities in mind, it is logical to target these actions to stop the progression of cartilage degradation in OA.
IL-1β can induce chondrocytes to produce proinflammatory mediators such as PGE2 and NO, as well as stimulating catabolic proteinases (MMPs or aggrecanases) [1–3]. NO is a crucial mediator of the inflammatory response by virtue of its physiological effects and its ability to regulate the expression of inflammatory proteins . In this way, they can alter compensatory biosynthetic homeostasis and break down the integrity of the ECM [4–7].
Recent studies have demonstrated that mitogen-activated protein kinases (MAPKs) play a key role in the cytokine regulation of MMP expression and consequent cartilage destruction . In OA cartilage, the level of phosphorylated MAPKs, including extracellular signal-regulated kinase (ERK), c-Jun amino-terminal kinase (JNK), and p38 appears to be higher than that in normal cartilage . MAPK pathways can be specifically activates downstream to over-production of MMP-1, -3, and −13, TNF-α, and NO [10–12]. However, the precise downstream mechanism is unknown, which limits effective therapeutic interventions in OA.
While various attempts have been made to develop disease-modifying OA drugs (DMOADs) that neutralize inflammatory cytokines and proteinases, enhance factors related to cartilage and bone homeostasis, and intervene in intracellular signaling pathways, the results to date have been unsatisfactory regarding the effects and safety of these drugs [13, 14]. The combination of systemic and topical administration of non-steroidal anti-inflammatory drugs (NSAIDs), steroids, glucosamine, and opioids is generally prescribed for OA patients, but current treatment options for more effective and safer management of chronic OA are insufficient [15–17]. Along with the alleviation of clinical symptoms, more effective therapeutic strategies to prevent the progression of disease and aid in the recovery of tissue damage are needed . As an alternative to the existing treatment, research into natural materials derived from herbs utilized for the safe cure for OA has been done.
To develop a novel OA treatment, we investigated the cartilage protection, analgesia, and anti-inflammation properties of 200 medicinal herbs used clinically for their anti-inflammatory and analgesic properties in traditional medicine. WIN-34B, a compound extracted from two herbs, the flowers of Lonicera japonica Thunb and roots of Anemarrhena asphodeloides BUNGE, was selected from the screen. WIN-34B demonstrated excellent anti-inflammatory, analgesic, and anti-osteoarthritic properties in the experimental animal models , and did not cause any acute or chronic toxicity or gastric mucosal damage in the animal models .
In this study, we investigated whether WIN-34B and its standard compounds have cartilage protective effects in IL-1β induced human cartilage explants culture. We assessed the viability of WIN-34B in the presence or absence of IL-1β-induced cartilage explants culture and chondrocytes, levels of GAG and type II collagen, histochemical features, levels of matrix proteinases [ADAMTSs, MMPs, and tissue inhibitors of matrix metalloproteinase (TIMPs)] and inflammatory mediators (PGE2, NO, IL-1β, and TNF-α) and the phosphorylation of MAPK signaling.
Preparation of WIN-34B
WIN-34B was prepared by extracting a mixture of two medicinal herbs (dried flowers of Lonicera japonica and dried roots of Anemarrhena asphodeloides) at a respective ratio of 2:1 (w/w) with 50% (v/v) ethanol for 4 h at 85°C. After the extracted solution was filtered and evaporated in vacuo, the resulting concentrate was dissolved in 225 ml of distilled water and partitioned with 195 ml of n-butanol. The n-butanol layer was evaporated in vacuo and lyophilized for complete removal of the residual solvent to give 11 g of brown powder, for a yield of 7%. WIN-34B was standardized for quality control according to a previous report .
High performance liquid chromatography (HPLC) analysis of WIN-34B
Cartilage explants culture
The collection of human OA cartilage was approved by medical ethical regulations of the Kyung Hee University Medical Center (KHMC-IACUC-2010011) and was obtained from the femoral chondyle and tibia plateau after nine patients undergoing total knee arthroplasty at the Kyung Hee University Medical Center provided consent. The average patient age was 62 years and patients included two males and seven females. NSAID medication was stopped 7 days before surgery and previous medication use was not expected to interfere with the studies. Two orthopedists read sites from all regions of the knee joint under a microscope. Only cartilage that appeared to be of full thickness with significant fibrillation was selected, so most joints appeared worse than the cartilage used here. Cartilage slices were aseptically cut as thick as possible from the articular bone surface, cut into square pieces, aseptically weighed (range 25 ± 0.1 mg), and cultured individually in 48-well plates with 400 μl of complete culture medium. The complete culture medium consisted of Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 mM HEPES, penicillin (100 IU/ml), streptomycin (100 μg/ml), and 5% fetal bovine serum (FBS). After 24 h, the cartilage medium was changed to basal culture medium (DMEM supplemented with 10 mM HEPES, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 2% FBS).
WIN-34B treatment of human cartilage explants culture
Experimental groups consisted of IL-1β-unstimulated control group, IL-1β-treated group (10 ng/ml), IL-1β-treated group with WIN-34B (40, 100, 200 μg/ml), IL-1β-treated group with chlorogenic acid (CA; 40, 100, 200 μg/ml; Sigma-Aldrich, St. Louis, MO, USA), and IL-1β-treated group with mangiferin (MF; 40, 100, 200 μg/ml; Sigma-Aldrich). Cartilage pieces were placed in 48-well plates and treated with 10 ng/ml human recombinant IL-1β (R&D Systems, Minneapolis, MN, USA) in basal culture medium. After 1 h of pretreatment, WIN-34B, CA, or MF was added to the basal culture media and then cultures were incubated in a humidified 5% CO2 incubator at 37°C. Reagents were replaced every 3 days, and supernatants were harvested at 7, 14, and 21 days. Supernatants were stored at −20°C until assayed.
As an indicator of cytotoxicity, the cytoplasmic enzyme lactate dehydrogenase (LDH) was measured in the culture medium. An optimized LDH test (Promega, Madison, WI, USA) was used to quantify LDH activity in the medium of the cartilage explants culture.
GAG degradation assay
The level of GAG in the cartilage explants culture medium at 7, 14, and 21 days was determined by measuring the amount of polyanionic material reacting with 1, 9-dimethylmethylene blue. Twenty microliter samples were mixed with 100 μl of DMB reagent (48 mg/ml DMB, 40 mM glycine, 40 mM NaCl, 10 mM HCl, pH 3.0) for 30 min at room temperature and quantified spectrophotometrically at 590 nm in a Spectramax apparatus (Molecular Devices, Sunnyvale, CA, USA). All measurements were performed in quadruplicate. Quantification was performed using a standard curve of chondroitin 6-sulfate from shark cartilage (Sigma-Aldrich) in the range of 0–35 μg/ml. Protein concentrations of the culture supernatants were also measured using the Bradford method (Pierce, Rockford, IL, USA) and then converted into μg/mg.
Type II collagen degradation assay
Type II collagen levels in the medium of the cartilage explants culture at 7, 14, and 21 days was determined using the Sircol Type II Collagen Assay Kit (Biocolor, Carrickfergus, Northern Ireland). Samples (100 μl) were mixed with Sirius red dye containing sulfonic acid, which reacts specifically with the basic side chain groups of type II collagens, for 30 min at room temperature using a mechanical mixer. After centrifuging for 10 min at 12,000 rpm, the unbound dye was removed, and the dye bound to type II collagen was dissolved in 0.5 N NaOH. Absorbance was measured at 540 nm using a Spectramax ELISA reader (Molecular Devices). All measurements were performed in quadruplicate. Concentrations were calculated using a standard curve in the range of 0–200 μg/ml with standards provided by the manufacturer.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Primer Design for Quantitative RT-PCR Analysis
Annealing Tm (cycle)
Rv: 5′-GGAGGTGGTAATTGCAGG GAACA-3′
Fw: 5’-GTCTGTGTC CAGGGCCGATGC-3’
Rv: 5’-AGTAGCC CATGCCATGCAGGA-3’
Rv: 5’-TAA AAA CAG CTC CGC ATC AA-3’
Fw: 5’-GCA ACTCCGACCTTGTCATC-3’
Cartilage explants pieces were fixed in 10% neutral formalin, dehydrated with graded ethanol, embedded in paraffin, and sectioned into 4 μm-thick slices. Sectioned tissues were deparaffinized and stained with Safranin O and Masson's Trichrome to detect proteoglycan and collagen in the cartilage. The staining intensities of Safranin O and Masson's Trichrome were quantified by i-solution program (IMT i-solution, Seoul Korea) after capture using an Axiocam MRc5 CCD camera (Carl Zeiss, Jena, Germany) at x40 magnification on histologic sections. A pathologist with no prior knowledge of the test reagents examined the stained slides.
Enzyme-linked immunosorbant assay (ELISA)
The levels of MMP-1, MMP-3, MMP-13, TIMP-1, TIMP-3, IL-1β, and TNF-α in conditioned media from OA cartilage explants at 7 days were measured using human ELISA kits (R&D Systems), according to the manufacturer's instructions.
Aggrecanase activity assay
Conditioned medium in cartilage explants at 7 days from the onset of culture was incubated in the presence of 1% w/v bovine serum albumin (BSA) in phosphate buffered saline (PBS)/Tween 20 (0.05% v/v) for 2 h at 25°C on a 96-well plate (Biosource) containing a monoclonal antibody that recognizes KS chains and, according to the manufacturer, is not impacted by other non-KS glycosaminoglycans, including hyaluronic acid, chondroitin sulfate, and heparin sulfate. Fragments containing ARGSVIL neoepitope were detected using biotinylated monoclonal antibody (mAb) OA-1 (PIERCE, Rockford, IL, USA). Levels of bound biotinylated mAb OA-1 were detected using 1 μg/ml streptavidin-horseradish peroxidase (HRP) and TMB as a substrate. Absorbance was determined following acidification using a microplate reader at a wavelength of 450 nm. Calibration curves for standard ARGSVIL peptide were run in parallel, and the amounts of ARGSVIL peptide produced in hydrolytic reactions were calculated from the calibration curves.
Measurement of PGE2
PGE2 production was determined from the supernatant of cultured OA cartilage explants at 7 days using assay kits (R&D Systems) performed per the manufacturer’s instructions.
Measurement of NO
NO synthesis was determined from the supernatant of cultured OA cartilage explants at 7 days by colorimetric assay as an indicator of NO production. Briefly, a 100 μl aliquot of medium was mixed with 100 μl of Greiss reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% naphthylethylenediamine dihydrochloride in water) (Sigma-Aldrich) in flat-bottom, 96-well immunoassay plates (SPL Life Sciences, Seoul, Korea). After incubating for 10 min at room temperature, absorption was measured at 550 nm with a Spectra Max 340 multichannel spectrophotometer (Molecular Devices). The nitrite concentration was determined from a standard curve generated using sodium nitrite (NaNO2).
Culture of chondrocytes and treatment
Chondrocytes were isolated from pooled femoral and tibial cartilage from individual OA patients by incubating with 1 mg/ml trypsin (Sigma-Aldrich) for 1 h followed by an overnight digestion in 0.5 mg/ml type II collagenase. The following morning, the isolated chondrocytes were washed with complete medium and counted at 1x106 cells/ml.
Cells were pipetted (100 μl, 1 × 105 cells/well) into a flat bottom 96-well culture plate and different concentrations of WIN-34B, chlorogenic acid, and mangiferin (10, 40, 100, 200, and 1000 μg/ml) were added in the presence or absence of 10 ng/ml IL-1β. After 48 h incubation at 37°C, 10 μl bromodeoxyuridine (BrdU) was added to each well, and the samples were incubated for 6 h at 37°C. Cells were fixed, anti-BrdU-peroxidase (POD) was added, and then detection was performed using the 3,3′,5,5′-tetramethylbenzidine (TMB) substrate reaction. The reaction product was quantified using an ELISA reader (480–650 nm).
Western blot analysis
For Western blot analysis of ADAMTS-4 and MAPK signaling pathways, pieces of cartilage explants culture were immediately frozen in liquid nitrogen and proteins in the resulting powder were extracted with Tris buffer (50 mM Tris, pH 7.0, 100 mM NaCl and 1 μg/ml aprotinin, 0.7 mg/ml pepstatin, 1 mg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride) for 12 h. Extract were lyophilized for 2 h to concentrate the proteins, and quantified by the Bio-Rad protein assay. Total protein (20 μg) was separated by electrophoresis by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a Hybond-C nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA). Blots were blocked in TBS-T containing 5% dry milk for 1 h. Thereafter, blots were probed with a polyclonal antibody against ADAMTS-4 (abcam-ab; Dawinbio, Seoul, Korea; 1:500 dilution), anti-phospho-ERK-1/2, phospho-p38, phospho-JNK, ERK, p38, and JNK (Cell Signaling Technology, Danvers, MA, USA), β-actin or non-immune mouse IgG (Sigma-Aldrich) in blocking buffer at 4°C overnight. Subsequently, each membrane was washed in TBS-T buffer five times for 5 min. Detection was carried out using anti-rabbit hoseradish peroxidase-conjugated IgG (Sigma-Aldrich, 1:5000 dilution) in blocking buffer. Blots were developed by enhanced chemiluminescence (ECL).
For measuring MMP-1, and MMP-13 expression level in IL-1β-stimulated cartilage explants culture, total secreted proteins from 2 ml of conditioned medium were harvested and concentrated by precipitation with trichloroacetic acid (TCA). Proteins (10 μg) were separated by 10% SDS-PAGE. Blots were treated as described above. Membrane were incubated with specific antibodies to MMP-1 and MMP-13 (Calbiochem, San Diego, CA, USA; 1:1000 dilution) in blocking buffer at 4°C overnight, and secondary antibody (Sigma, 1:5000) for 2 h at room temperature. Band intensities were quantified by NIH ImageJ 1.32j (National Institute of Health, USA) software.
Results are expressed as the mean ± SEM. Differences among groups were analyzed by one-way ANOVA followed by Dunnett’s post-hoc test. In the case of two groups, a Student's t-test was used. Statistical significance was assessed at p < 0.05. Experiments were independently triplicated and results were qualitatively identical. Representative experiments are shown.
Effect of WIN-34B on the cytotoxicity of cartilage explants culture and chondrocytes
Effect of WIN-34B on the level of proteoglycan and type II collagen in IL-1β-stimulated cartilage explants culture
Effect of WIN-34B on the levels of aggrecanases, MMPs, and TIMPs in IL-1β-stimulated cartilage explants culture
Effects of WIN-34B on inflammatory mediators in IL-1β-stimulated cartilage explants culture
Effect of WIN-34B on phosphorylation of MAPKs in IL-1β-stimulated cartilage explants culture
A problem in using natural herbal material is the difficulty in standardization of efficacy, which is partially due to factors such as differences in region of origin, harvest period, and cultivation time. Also, for the discovery and development of new treatments, further understanding of the processes leading to disease progression and in particular, the pathways leading to the expression of the MMPs, aggrecanases, and cartilage destruction are of pivotal importance. Therefore, we measured the major components and examined their efficacy to set a standard for use of WIN-34B in practice and in medicine development. In this study, we demonstrated the cartilage-protective effects of WIN-34B compared to standard compounds, CA and MF, in IL-1β-stimulated cartilage explants culture. WIN-34B more effectively improved the cartilage protection without cytotoxicity by modulating MMPs, ADADMTs, TIMPs, and inflammatory mediators, and possibly by inhibiting MAPK pathways.
WIN-34B did not exert cytotoxic effects in the absence of IL-1β in human OA cartilage explants culture and did not affect cell viability in chondrocytes. However, CA was cytotoxic in human cartilage explants culture and chondrocytes.
Previously, we found that even high doses of WIN-34B did not cause toxicity or gastric injury when orally administered to rats . Both single and multiple doses of WIN-34B had no effect on mortality, body weight changes, gross findings, or clinical signs in patients of either sex . This finding was in contrast to those for diclofenac and celecoxib, which cause inflammation and hemorrhage [19, 20]. Furthermore, clinical study on patients with OA revealed that WIN-34B not only had a good analgesic efficacy and safety profile, but also showed functional improvements on the time taken to go up and down a standard flight of stairs, duration of morning stiffness, and softening of the affected knee joint. These results support the safety and therapeutic usefulness of WIN-34B for development as an OA treatment.
WIN-34B markedly prevented the release of GAG and type II collagen, which are associated with the down-regulation of matrix proteinases (MMP-1, MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5), inflammatory cytokines (PGE2, NO, IL-1β, and TNF-α), and up-regulation of TIMP-1 and TIMP-3 levels in IL-1β-stimulated human OA cartilage culture. However, CA and MF significantly inhibited only collagen release, which is associated with the inhibition of MMP-1, MMP-13, and inflammatory cytokines in IL-1β-stimulated human OA cartilage culture. The inhibition of GAG release and recovery of aggrecan expression by CA and MF was not evident in IL-1β-stimulated human OA cartilage culture. Therefore, we suggest that WIN-34B could be a potential candidate for effective anti-osteoarthritic therapy with cartilage protective properties better than CA or MF.
Protecting ECM components is critical to modifying OA progression and protecting joint functions [21, 22]. A number of studies have documented the fact that aggrecan not only resists mechanical loading by enabling the cartilage matrix to attract and imbibe water molecules, but also plays a partial role in preventing collagen degradation in OA pathogenesis [21, 23, 24]. For this reason, many researchers have investigated the OA-modifying effects of drugs designed to inhibit ADAMTS-4 and ADAMTS-5 . Several studies have reported that glucosamine down-regulates ADAMTS and MMPs including MMP-3, MMP-9, MMP-10, and MMP-12 [25, 26]. SKI306X, a commercially-available herbal mixture for OA treatment, inhibits cartilage degradation through the production of MMPs and inflammatory mediators . Inflammatory mediators, such as PGE2, NO, IL-1, and TNF-α, play key roles in the progression of cartilage destruction in OA [28, 29]. Particularly, IL-1β produces PGE2 and NO, and stimulates the expression of other inflammatory cytokines and MMPs . PGE2 is a pathologic mediator responsible for the remodeling of cartilage and bone . NO is a pleiotropic mediator involved in the catabolic process of OA, which inhibits the synthesis of proteoglycan and collagen, resulting in the promotion of cartilage destruction . Presently, WIN-34B decreased the level of inflammatory mediators including PGE2 and NO, as well as the proinflammatory cytokines, IL-1β, and TNF-α, which are all recognized as inducers of MMPs and aggrecanases. The inhibition of PGE2 release, NO production, and TNF-α secretion by WIN-34B was superior to CA or MF. These results suggest that WIN-34B inhibits the pathologic inflammatory molecules in the cartilage destruction of OA.
MAPKs regulate pro-inflammatory cytokine production and downstream signaling cascades leading to catabolic joint destruction [8, 30]. Studies in human cells have suggested that MAPK signaling is important for the MMP-derived catabolic response of chondrocytes. Liacini et al. showed that TNF-stimulated human OA chondrocytes up-regulated expression of MMP-13, through MAPK 44/42 and Janus-NH2-terminal kinase JNK . Similar results in human chondrosarcoma cells supported these findings . Taken together, these findings suggest that MAPK signaling is important for the MMP-derived catabolic response of chondrocytes. Recently reported that intra-articular injections of the p38 MAPK inhibitor SB203580 in the anterior cruciate ligament transection (ACLT) rat model of OA inhibited the expression of MMP-3 and MMP-13 and protected against cartilage damage . Other research showed WIN-34B dose-dependently diminished phosphorylation of ERK, JNK, and p38 MAPK, as well as MMPs and aggrecanases in IL-1β-stimulated cartilage explants culture. However, CA and MF increased phosphorylation of p38 and suppressed phosphorylation of JNK, but did not affect the phosphorylation of ERK. Inhibition of the MAPK P44/42 pathway by either U0126 or PD98059 leads to abrogation of the expression and activity of MMPs and aggrecanases and ADAMTS. Inhibitors of the p38 MAPK and JNK pathways were also investigated by SB203580 or SB202190 and PP1, respectively. However, inhibition of these pathways resulted in inhibition of MMP expression and activity, but did not influence aggrecanases activity . The current line of investigations suggests that p38 MAPK and JNK activity could be associated with MMP-mediated irreversible cartilage damage, whereas the processes needed for normal repair mechanism and aggrecanase activity may in part be controlled by MAPK p44/42-activities [33, 34]. From these results we can suggest that WIN-34B may be critical role on cartilage protection and anti-inflammatory effect by the downregulation of pERK, p38 MAPK and pJNK signaling pathways.
WIN-34B has cartilage protective effects similar to or better than its standard compound CA or MF through the regulation of matrix proteinases (aggrecanases and MMPs/TIMPs), inflammatory mediators (PGE2, NO, IL-1β, and TNF-α) and the MAPK pathways. These results suggest that WIN-34B could be a potential candidate for effective anti-osteoarthritic therapy with cartilage protective properties and without toxicity instead of existing OA treatment.
This work was supported by a grant from Kyung Hee University in 2011 (KHU-20110063), and This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011–0006033).
- Krasnokutsky S, Attur M, Palmer G, Samuels J, Abramson SB: Current concepts in the pathogenesis of osteoarthritis. Osteoarthr Cartil. 2008, 16 (Suppl 3): S1-S3.View ArticlePubMed
- Tetlow LC, Adlam DJ, Woolley DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001, 44 (3): 585-594. 10.1002/1529-0131(200103)44:3<585::AID-ANR107>3.0.CO;2-C.View ArticlePubMed
- Fernandes JC, Martel-Pelletier J, Pelletier JP: The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002, 39 (1–2): 237-246.PubMed
- Goldring MB, Goldring SR: Osteoarthritis. J Cell Physiol. 2007, 213 (3): 626-634. 10.1002/jcp.21258.View ArticlePubMed
- Goldring MB, Otero M: Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011, 23 (5): 471-478. 10.1097/BOR.0b013e328349c2b1.PubMed CentralView ArticlePubMed
- Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H: Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011, 7 (1): 33-42. 10.1038/nrrheum.2010.196.View ArticlePubMed
- Samuels J, Krasnokutsky S, Abramson SB: Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis. 2008, 66 (3): 244-250.PubMed
- Thalhamer T, McGrath MA, Harnett MM: MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford). 2008, 47 (4): 409-414.View Article
- Boileau C, Martel-Pelletier J, Brunet J, Schrier D, Flory C, Boily M, Pelletier JP: PD-0200347, an alpha2delta ligand of the voltage gated calcium channel, inhibits in vivo activation of the Erk1/2 pathway in osteoarthritic chondrocytes: a PKCalpha dependent effect. Ann Rheum Dis. 2006, 65 (5): 573-580. 10.1136/ard.2005.041855.PubMed CentralView ArticlePubMed
- Geng Y, Valbracht J, Lotz M: Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. J Clin Invest. 1996, 98 (10): 2425-2430. 10.1172/JCI119056.PubMed CentralView ArticlePubMed
- Liacini A, Sylvester J, Li WQ, Huang W, Dehnade F, Ahmad M, Zafarullah M: Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res. 2003, 288 (1): 208-217. 10.1016/S0014-4827(03)00180-0.View ArticlePubMed
- Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE: Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000, 43 (4): 801-811. 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4.View ArticlePubMed
- Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, Blair SN, Berman BM, Fries JF, Weinberger M, Lorig KR, Jacobs JJ, Goldberg V: Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med. 2000, 133 (9): 726-737.View ArticlePubMed
- Dougados M: Why and how to use NSAIDs in osteoarthritis. J Cardiovasc Pharmacol. 2006, 47 (Suppl 1): S49-S54.View ArticlePubMed
- Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA: Osteoarthritis - an untreatable disease?. Nat Rev Drug Discov. 2005, 4 (4): 331-344. 10.1038/nrd1693.View ArticlePubMed
- Malemud CJ, Goldberg VM: Future directions for research and treatment of osteoarthritis. Front Biosci. 1999, 15 (4): D762-D771.
- Malemud CJ: Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging. 2010, 27 (2): 95-115. 10.2165/11319950-000000000-00000.View ArticlePubMed
- Khalife S, Zafarullah M: Molecular targets of natural health products in arthritis. Arthritis Res Ther. 2011, 13 (1): 102-10.1186/ar3222.PubMed CentralView ArticlePubMed
- Kang M, Jung I, Hur J, Kim SH, Lee JH, Kang JY, Jung KC, Kim KS, Yoo MC, Park DS, Lee JD, Cho YB: The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo. J Ethnopharmacol. 2010, 131 (2): 485-496. 10.1016/j.jep.2010.07.025.View ArticlePubMed
- Huh JE, Lee WI, Seo BK, Baek YH, Lee JD, Choi DY, Park DS: Gastroprotective and safety effects of WIN-34B, a novel treatment for osteoarthritis, compared to NSAIDs. J Ethnopharmacol. 2011, 137 (2): 1011-1017. 10.1016/j.jep.2011.07.025.View ArticlePubMed
- Caterson B, Flannery CR, Hughes CE, Little CB: Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 2000, 19 (4): 333-344. 10.1016/S0945-053X(00)00078-0.View ArticlePubMed
- Umlauf D, Frank S, Pap T, Bertrand J: Cartilage biology, pathology, and repair. Cell Mol Lif Sci. 2010, 67 (24): 4197-4211. 10.1007/s00018-010-0498-0.View Article
- Dudhia J: Aggrecan, aging and assembly in articular cartilage. Cell Mol Life Sci. 2005, 62 (19–20): 2241-2256.View ArticlePubMed
- Fosang AJ, Little CB: Drug insight: aggrecanases as therapeutic targets for osteoarthritis. Nat Clin Pract Rheumatol. 2008, 4 (8): 420-427.View ArticlePubMed
- Gouze JN, Gouze E, Popp MP, Bush ML, Dacanay EA, Kay JD, Levings PP, Patel KR, Saran JP, Watson RS, Ghivizzani SC: Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther. 2006, 8 (6): R173-10.1186/ar2082.PubMed CentralView ArticlePubMed
- Deniz M, Oegema TR, Schiffman EL, Look JO: The effect of exogenous glucosamine hydrochloride on the proteoglycan concentration of the articular disc of the rabbit temporomandibular joint. J Orofac Pain. 2003, 17 (3): 251-253.PubMed
- Martel-Pelletier J, Alaaeddine N, Pelletier JP: Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci. 1999, 15 (4): D694-D703.View Article
- Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D: Cyclooxygenase2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum. 2002, 46 (7): 1789-1803. 10.1002/art.10356.View ArticlePubMed
- Cake MA, Read RA, Appleyard RC, Hwa SY, Ghosh P: The nitric oxide donor glyceryl trinitrate increase subchondral bone sclerosis and cartilage degeneration following ovine menisectomy. Osteoarthr Cartil. 2004, 12 (12): 974-981. 10.1016/j.joca.2004.08.012.View ArticlePubMed
- Loeser RF, Erickson EA, Long DL: Mitogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr Opin Rheumatol. 2008, 20 (5): 581-586. 10.1097/BOR.0b013e3283090463.PubMed CentralView ArticlePubMed
- Yoon SW, Chun JS, Sung MH, Kim JY, Poo H: Alpha-MSH inhibits TNF-alpha-induced matrix metalloproteinase-13 expression by modulating p38 kinase and nuclear factor kappaB signaling in human chondrosarcoma HTB-94 cells. Osteoarthr Cartil. 2008, 16 (1): 115-124. 10.1016/j.joca.2007.05.026.View ArticlePubMed
- Chen WD, Jiang Q, Chen DY, Xu H, Zhang YF: Effects of intra-articular injection of p38 mitogen-activated protein kinase inhibitor on matrix metalloproteinase in articular cartilage of a rat model of osteoarthritis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2007, 29 (6): 777-781.PubMed
- Sondergaard BC, Schultz N, Madsen SH, Bay-Jensen AC, Kassem M, Karsdal MA: MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation–divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthr Cartil. 2010, 18 (3): 279-288. 10.1016/j.joca.2009.11.005.View ArticlePubMed
- Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC: Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther. 2008, 10 (3): R63-10.1186/ar2434.PubMed CentralView ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/256/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.